We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ITT:NYSEITT Inc. Analysis

Data as of 2026-05-19 - not real-time

$194.98

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

ITT delivered a robust 32.7% revenue growth year‑over‑year, with a 35.4% gross margin and a 17% operating margin, while forward EPS of $9.20 outpaces trailing EPS of $5.67, compressing the forward PE to 21 versus a trailing PE of 34.4. The recent acquisition of SPX FLOW is already being credited for “solid momentum across the portfolio,” reinforcing the earnings upside.
The stock is trading at $194.98, just above the 200‑day SMA (186) but below the 20‑day SMA (210). RSI sits at 34, indicating oversold conditions, while the MACD histogram remains negative, pointing to short‑term bearish pressure. Volatility is elevated at 33.8% over the past 30 days and beta around 1.3, underscoring heightened price swings. A DCF‑derived fair value of $62.36 and a PE above the industry average (34.4 vs 29.5) suggest the market may be overvaluing the shares.
The dividend yield of 0.79% is backed by a modest 25% payout ratio and strong operating cash flow, supporting dividend sustainability. Nevertheless, a debt‑to‑equity ratio of 83.5% and higher interest expense from the SPX FLOW deal introduce leverage risk. The Fear & Greed Index reading of 89.6 (“Extreme Greed”) reflects strong market optimism despite these mixed fundamentals.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support at $193.28
  • Oversold RSI suggesting limited downside
  • High volatility and bearish MACD histogram

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth and improving forward EPS
  • Synergies from the SPX FLOW acquisition
  • Sustainable dividend with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Durable cash flow generation and solid ROE
  • Broad global footprint across industrial segments
  • Long‑term upside potential despite current overvaluation

Key Metrics & Analysis

Financial Health

Revenue Growth32.70%
Profit Margin10.80%
P/E Ratio34.4
ROE12.26%
ROA5.99%
Debt/Equity83.55
P/B Ratio4.1
Op. Cash Flow$594.6M
Free Cash Flow$252.9M
Industry P/E29.5

Technical Analysis

TrendBullish
RSI34.9
Support$193.28
Resistance$225.26
MA 20$210.09
MA 50$202.38
MA 200$186.17
MACDBearish
VolumeIncreasing
Fear & Greed Index89.61

Valuation

Fair Value$62.36
Target Price$244.77
Upside/Downside25.54%
GradeOvervalued
TypeGrowth
Dividend Yield0.79%

Risk Assessment

Beta1.23
Volatility33.79%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.